Knowledge hub
Articles from the Molekula editorial team
Coverage of chemistry, regulatory updates, methods, supply-chain insight, and product spotlights. New articles published daily.
-
Supplier-news
Red Sea and Suez disruptions in 2026: rerouting risks for Asian fine‑chemical shipments
In 2026 the Red Sea and Suez Canal blockages added up to 12 days of delay and forced many Asian fine‑chemical consignments to detour via the Cape of Good Hope. The rerouting increased freight costs by 15‑25 % and introduced temperature‑control and security challenges that can affect product integrity and supply‑chain reliability.
Oct 18, 2026 · 5 min read -
Supplier-news
Sourcing High‑Purity Rare Isotopes for Radiopharmaceuticals Amid Global Shortages
High‑purity rare isotopes for radiopharmaceuticals can still be sourced despite worldwide shortages by diversifying suppliers, using alternative production routes, and implementing strict quality‑control protocols. Key actions include engaging multiple certified manufacturers, verifying ISO/REACH compliance, and maintaining a validated inventory management system.
Oct 2, 2026 · 5 min read -
Supplier-news
Evaluating the Resilience of African API Hubs After Recent Trade Disruptions
African active pharmaceutical ingredient (API) hubs have shown mixed resilience to recent trade disruptions. While some hubs have maintained output through local sourcing and inventory buffers, others face capacity constraints due to import delays, logistics bottlenecks and regulatory challenges, as highlighted by UNCTAD and Afreximbank analyses.
Sep 20, 2026 · 4 min read -
Supplier-news
Supplier qualification checklist for GMP‑grade isotopically labelled compounds in 2026
A robust supplier qualification checklist for GMP‑grade isotopically labelled compounds in 2026 must verify regulatory compliance (ISO 9001:2015, ISO 13485, GMP, REACH, TSCA), assess quality systems, confirm analytical capability (NMR, HPLC, GC‑MS), and evaluate documentation such as CoA, SDS and audit history.
Sep 19, 2026 · 4 min read -
Supplier-news
Strategic sourcing of rare earth catalysts amid geopolitical tensions in 2026
Rare earth catalysts remain essential for fine‑chemical and biopharmaceutical processes, but 2026 geopolitical tensions have tightened supply chains. China still supplies the majority, while export controls and trade disputes increase lead times and price volatility. Diversified sourcing, recycling, and alternative chemistries are the primary risk‑mitigation strategies.
Aug 27, 2026 · 4 min read -
Supplier-news
Buffer and Reducing‑Agent Supply (DTT/TCEP/HEPES/Tris): Sourcing and Quality in 2026
In 2026, DTT and TCEP remain the principal disulphide‑reducing agents, with TCEP offering greater pH stability and longer shelf‑life, while DTT is cheaper but oxidises rapidly. HEPES and Tris buffers are widely available from multiple GMP‑certified manufacturers, with purity specifications of ≥99.5 % and consistent ISO‑9001 compliance. Regulatory frameworks (REACH, USP, EP) continue to dictate documentation and testing requirements.
Aug 24, 2026 · 5 min read -
Supplier-news
Biocatalysis and Enzyme Engineering in Pharma Synthesis: What Is Changing Procurement?
Biocatalysis and enzyme engineering are reshaping pharmaceutical manufacturing, prompting procurement teams to prioritise supplier reliability, regulatory compliance, and sustainability. Procurement now evaluates enzyme activity data, batch‑to‑batch consistency, and life‑cycle impact, while negotiating flexible contracts to accommodate rapid process optimisation.
Aug 23, 2026 · 4 min read -
Supplier-news
Semiconductor‑grade chemical shortages and their knock‑on effects for high‑purity reagents
The semiconductor industry is experiencing a shortage of high‑purity, semiconductor‑grade chemicals due to heightened demand and limited production capacity. This scarcity cascades into biotech and pharmaceutical labs, restricting access to critical reagents and prompting supply‑chain adjustments.
Aug 21, 2026 · 3 min read -
Supplier-news
Cold‑chain and biologics logistics pressures shaping reagent and excipient sourcing in 2026
Cold‑chain constraints and the increasing complexity of biologics logistics are driving changes in how reagents and excipients are sourced in 2026. Suppliers must prioritise temperature‑stable grades, regulatory compliance, and supply‑chain resilience to meet tighter stability windows and global distribution demands.
Aug 18, 2026 · 5 min read -
Supplier-news
GLP‑1 demand and the specialty‑chemical squeeze for peptide synthesis reagents
GLP‑1 analogue sales surpassed $10 bn in 2023, driving a sharp rise in peptide manufacturing. This surge strains the supply of high‑purity reagents such as Fmoc‑protected amino acids and coupling agents, leading to longer lead times and price increases across the specialty‑chemical market.
Aug 7, 2026 · 4 min read -
Supplier-news
China and India API Manufacturing Shifts in 2026 and Their Implications for Western Procurement
By 2026, China is expected to reduce its share of global API output to around 30% from 45% in 2022, while India aims to increase capacity by 20‑25% to meet rising demand. These shifts will pressure Western buyers to diversify supply chains, reassess risk matrices, and adopt stricter quality‑by‑design controls.
Aug 6, 2026 · 5 min read -
Supplier-news
Building a Long-Term Supply Partnership for Biotech R&D
Establishing a reliable, scalable supply partnership is critical for biotech R&D. Key factors include consistent quality (verified via CoA, HPLC, NMR), regulatory compliance (ISO, REACH, TSCA), and transparent communication. Long-term agreements with traceable documentation and flexible scaling support innovation without supply chain disruption.
Jun 29, 2026 · 4 min read